Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-05-23
2006-05-23
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S912000
Reexamination Certificate
active
07049340
ABSTRACT:
The invention concerns a neuroprotective and retinoprotective medicine, whereof the active principle is selected among a group of compounds consisting of ramipril, ramiprilat or any other ramiprilat derivative capable of releasing it in the organism whereto it is administered. Said medicine is used for prevention, or even for improving visual acuity and visual field in normal subjects, as well as for treating ophthalmologic pathologies involving a vascular factor, in particular glaucomatous neuropathy, degenerative choriopathy of strong myopia, age-related maculopathy, serous central chorioretinopathy, hereditary dystrophy of the retina and retinal venous occlusions. It almost invariably improves the visual function (acuity and visual field).
REFERENCES:
patent: 0 114 333 (1983-12-01), None
patent: 0 158 157 (1985-03-01), None
patent: 0 220 107 (1986-10-01), None
patent: WO 99/36062 (1999-07-01), None
H.P. Chase et al, “Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial”, Annals of ophthalmology, (Aug. 1993) 25 (8) pp. 284-289.
Bunning “Inhibition of Angiotensin Converting Enzyme by 2-[N-[(S)-1-carboxy-3-penoxy]-L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octaine-3-carboxylic acid (HOE 498 Diacid) Comparison with Captopril and Enalaprilat”, Arzneim-Forsch./Drug Research, 34;1406-1410; (1984).
Database WPI Section Ch, Week 199401, “Peptides of Formulae Gly-His-Phe (I) and Tyr-Arg-Pro-Tyr (II) Inhibit Angiotensin I Converting Enzyme (ACE)”, Derwent Publication Ltd., London, GB; Class B03, AN 1994-002154 XP002157734.
Detry-Morel, “Perspectives in the Medical Treatment of Glaucomatous Neuropathy Bases for Neuroprotection”, J. Fr. Ophtmalmol., 22(1):122-134; (1999) XP-00087-144 (translation attached).
Garg et al., “Renal and Retinal Changes after Treatment with Ramipril and Pentoxifyline in Subjects with IDDM”, Ann. Ophthalmol., 30(1):33-37; (1998) XP-000980142.
Shah et al., “Ocular Hypotensive Effect of Ramiprilat in Chronic and Acute Models of Glaucoma in Rabbits”, Indian Journal of Pharmacology, 31:110-115; (1999) XP-00980134.
Kulshrestha et al., “Protective Effect of Angiotensin Converting Enzyme Inhibitors in Diabetic Retinopathy”, IVOS, 40(4):312; (1999) XP-00980128.
Kusaka-Nakamura et al., “Antihypertensive Treatment in Spontaneously Hypertensive Rats with Streptozotocin-Induced Diabetes Mellitus”, Acta Physiol. Hung. 71(2):251-269; (1988) XP-000980228.
Vasmant et al., “Renin-Angioistensin System and A New Converting Enzyme Inhibitor”, J. of Cardiovascular Pharmacology 14 (suppl. 4): 546-552; (1989).
Vogh et al., “Effects of Inhibition of Angiotensin Converting Enzyme and Carbonic Anhydrase on Fluid Production by Ciliary Process, Choroid Plexus, and Pancreas”, J. of Ocular Pharmacology 5(4);303-311; (1989) XP-00980132.
Yamagami et al., “Captopril”, Dept. of Ophthalmology, Hirosaki Univ. School of Med., 34:290-297; (1983) XP-000980116.
Holman et al., “Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39,” BMJ 317:713-720 (1998).
Clark & Elbing LLP
Weddington Kevin E.
LandOfFree
Neuroprotective and retinoprotective ophthalmologic drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotective and retinoprotective ophthalmologic drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective and retinoprotective ophthalmologic drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3574708